Payment overview · 2025
General Payments
$39.31
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mitchell Jason Marder, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1285673319
Verified facts
What the public records show
CMS Open Payments records show Mitchell Jason Marder, D.O. received $39.31 in general payments during 2025 across 2 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.45 | 54.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.86 | 45.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $39.31 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 58 |
| Gabapentin | Gabapentin | 223 | 42 |
| Losartan Potassium | Losartan Potassium | 217 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 56 |
| Omeprazole | Omeprazole | 214 | 59 |
| Metformin Hcl | Metformin Hcl | 178 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 37 |
| Lisinopril | Lisinopril | 157 | 41 |
| Ezetimibe | Ezetimibe | 147 | 44 |
| Simvastatin | Simvastatin | 147 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 33 |
| Alendronate Sodium | Alendronate Sodium | 124 | 32 |
| Eliquis | Apixaban | 124 | 24 |
| Furosemide | Furosemide | 123 | 42 |
| Montelukast Sodium | Montelukast Sodium | 109 | 22 |
| Trazodone Hcl | Trazodone Hcl | 107 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 27 |
| Carvedilol | Carvedilol | 95 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 13 |
| Metformin Hcl Er | Metformin Hcl | 82 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 20 |
| Azithromycin | Azithromycin | 78 | 66 |
| Famotidine | Famotidine | 78 | 26 |
| Lorazepam | Lorazepam | 77 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 76 | 25 |
| Januvia | Sitagliptin Phosphate | 76 | 11 |
| Meloxicam | Meloxicam | 76 | 21 |
| Jardiance | Empagliflozin | 73 | 18 |
| Bupropion Xl | Bupropion Hcl | 72 | 21 |
| Potassium Chloride | Potassium Chloride | 70 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 22 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Glimepiride | Glimepiride | 58 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 14 |
| Ibuprofen | Ibuprofen | 56 | 19 |
| Alprazolam | Alprazolam | 52 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | 19 |
| Valsartan | Valsartan | 48 | 14 |
| Synthroid | Levothyroxine Sodium | 47 | 11 |
| Clonazepam | Clonazepam | 46 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Ozempic | Semaglutide | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Amoxicillin | Amoxicillin | 34 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Nystatin | Nystatin | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Naproxen | Naproxen | 25 | 13 |
| Atenolol | Atenolol | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 22 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fluconazole | Fluconazole | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Temazepam | Temazepam | 16 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.31 · 2 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, JARDIANCE, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error